#India #Intas Pharmaceuticals #Ahmedabad #Prothya Biosolutions #Accord Plasma

Intas and Accord's Strategic Acquisition of Prothya Biosolutions

In a pivotal move towards strengthening their global standing in the plasma-derived medicinal products (PDMP) sector, Intas Pharmaceuticals, through its subsidiary Accord Plasma B.V., has finalized an agreement to acquire 100% ownership of Prothya Biosolutions. This acquisition, pending customary regulatory approvals, is expected to close imminently.

Expansion into European Markets

Prothya Biosolutions operates from Amsterdam and Brussels, with plasma collection centers across Hungary and employs around 1,200 staff. The company is recognized as one of Europe’s leading plasma fractionators and was established in 2021 through the merger of Plasma Industries Belgium and Sanquin Plasma Products. With over 60 years of expertise, Prothya brings a wealth of experience in plasma donation and the manufacturing of vital therapeutic products.

Binish Chudgar, Chairman of Intas and Accord, expressed enthusiasm over this acquisition, highlighting that it represents a remarkable opportunity to expand their capabilities in the plasma sector globally. He stated, “By combining our fractionation expertise in India with Prothya’s operations, we are set to develop a comprehensive global plasma solution that will benefit patients across various markets.”

A Significant Growth Opportunity

Intas’s plasma division has been a key player in the Indian market since 2015, providing an annual capacity to fractionate over one million liters of plasma. The planned expansion of Intas’s facility in Gujarat will further bolster their production capabilities. The acquisition signifies Intas and Accord’s long-term ambition to not only enhance their service offerings but also capture a growing share of the global PDMP market, which is valued at $30 billion and projected to grow to $50 billion by 2035.

Nir Epstein, CEO of Prothya, reflected on the last few years of transformation within Prothya, which have seen them pioneer new market frontiers and advance critical therapy development. He remarked, “With our established plasma collection networks and strong commitment to excellence, we believe that aligning with Accord will propel us into the next phase of growth and international expansion.”

Strong Financial Backing and Future Prospects

The industrial alliance is supported by BofA Securities and Evercore, who serve as financial advisors to Accord and Prothya, respectively. This collaboration not only promises to enhance the service jitney but also aligns two innovation-driven companies in the pharmaceutical industry towards meeting worldwide healthcare needs.

As the landscape of healthcare continues to evolve, the merger between Intas and Prothya positions them to respond effectively to the increasing demand for PDMPs, specifically intravenous immunoglobulin therapies that remain critical but often under-prescribed. With a combined breadth of market reach touching 85 countries, the newly formed entity will capitalize on shared expertise and geographical strengths to cater to patients globally, promoting higher accessibility and responsiveness in healthcare delivery.

Conclusion

The acquisition of Prothya Biosolutions is a bold step for Intas and Accord, marking a significant milestone in their journey to enhance global healthcare access. This strategic move underscores their commitment to meeting the diverse therapeutic needs of patients around the globe, reinforcing their stature as leaders in the pharmaceutical arena. As they work towards completing this transaction, the anticipation grows for how this will reshape the PDMP market landscape.